Glioblastoma Stem Cells as a Therapeutic Target
Cancer Stem Cells: New Horizons in Cancer Therapies, Page: 167-184
2020
- 4Citations
- 1Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Glioblastoma (GBM) is a deadly brain tumor with poor prognosis despite the improvement in the diagnosis of GBM and innovative treatment strategies. Chemotherapy and radiotherapy could only help the GBM patients to a mean survival of 15 months. One of the key reasons for this poor outcome is a complex tumor heterogeneity and the presence of cancer stem cells (CSCs). CSCs in GBM (GSCs) are responsible for drug resistance and relapse. Cancer cells (non-GSC)are normally sensitive to drug treatment, whereas GSCs are resistant to treatment. This chapter describes the complexity of GSC and their microenvironment niche, GSCs as a therapeutic target, and details on clinical trials that target GSCs. This knowledge may help us in better understanding CSCs in glioblastoma and developing new therapeutic strategies for this deadly disease.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85151194645&origin=inward; http://dx.doi.org/10.1007/978-981-15-5120-8_10; https://link.springer.com/10.1007/978-981-15-5120-8_10; https://dx.doi.org/10.1007/978-981-15-5120-8_10; https://link.springer.com/chapter/10.1007/978-981-15-5120-8_10
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know